CORRESP Filing
ONCOLYTICS BIOTECH INC
Date: Aug. 27, 2025 · CIK: 0001129928 · Accession: 0001104659-25-084052
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289819
Letter
ONCOLYTICS BIOTECH INC.
Suite 804, 322 11th Avenue SW
Calgary, Alberta, Canada, T2R 0C5
VIA EDGAR
August 27, 2025
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Tyler Howes
Re:
Oncolytics Biotech Inc.
Registration Statement on Form F-3
File No. 333-289819
To the addressee set forth above:
Pursuant to Rule 461 of the U.S. Securities Act of 1933, as amended, Oncolytics Biotech Inc. (the "Company") hereby requests acceleration of the effective date of its registration statement on Form F-3 (File No. 333-289819) (the "Registration Statement"), to 4:00 p.m. Eastern Time on August 29, 2025, or as soon thereafter as practicable.
Please contact Christopher J. Clark of Latham & Watkins LLP, special U.S. counsel to the Company, at (202) 637-2374 or Christopher.J.Clark@lw.com, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Very truly yours,
ONCOLYTICS BIOTECH INC.
Show Raw Text
CORRESP 1 filename1.htm ONCOLYTICS BIOTECH INC. Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada, T2R 0C5 VIA EDGAR August 27, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Oncolytics Biotech Inc. Registration Statement on Form F-3 File No. 333-289819 To the addressee set forth above: Pursuant to Rule 461 of the U.S. Securities Act of 1933, as amended, Oncolytics Biotech Inc. (the "Company") hereby requests acceleration of the effective date of its registration statement on Form F-3 (File No. 333-289819) (the "Registration Statement"), to 4:00 p.m. Eastern Time on August 29, 2025, or as soon thereafter as practicable. Please contact Christopher J. Clark of Latham & Watkins LLP, special U.S. counsel to the Company, at (202) 637-2374 or Christopher.J.Clark@lw.com, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. Very truly yours, ONCOLYTICS BIOTECH INC. By: /s/ Kirk Look Name: Kirk Look Title: Chief Financial Officer cc: Christopher J. Clark, Esq., Latham & Watkins LLP